To learn about our efforts to improve the accessibility and usability of our website, please visit our Accessibility Information page. Skip to main content
MLB.com

Press Release

12/01/2010 5:46 PM ET
Independent program administrator issues annual report

On Wednesday, Major League Baseball and the Major League Baseball Players Association released the following annual public report from the Joint Drug Prevention and Treatment Program's independent program administrator.

The accompanying report from the independent program administrator, Bryan W. Smith, M.D., Ph.D., covers the period from the beginning of the 2009-2010 offseason through the end of Major League Baseball's 2010 postseason.

2010 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2009-2010 Major League Baseball offseason to the end of the 2010 MLB postseason.

As per agreement between Major League Baseball and the Major League Baseball Players Association, the following report is specific to players who compose 40-man rosters for Major League Baseball clubs.

1) The number of drug tests that were collected and analyzed for performance-enhancing substances and/or stimulants during the time listed above was 3,747 tests.

2) Seventeen tests were reported by the testing laboratory for having an adverse analytical finding that resulted in discipline. The substances reported were as follows:

Performance-enhancing substances (2)
Clomiphene (1)
Oxandrolone (1)

Stimulants (15)
Adderall (13)
Clobenzorex (1)
Phentermine (1)

3) 110 Therapeutic Use Exemptions were granted. The diagnoses were as follows:

Attention Deficit Disorder: 105
Hypertension: 2
Hypogonadism: 1
Narcolepsy: 1
Post-concussion syndrome: 1

Respectfully submitted,
Bryan W. Smith, M.D., Ph.D.
Independent Program Administrator
Major League Baseball’s Joint Drug Prevention and Treatment Program